Orexo starts clinical study of nasal rescue medication – challenging established market

Allergy firm ALK could face new competition on the market for the emergency treatment of allergic reactions, as the Swedish biotech firm will test its nasal candidate against today’s first-line, intramuscular injection treatments.

Nikolaj Sørensen, CEO of Orexo | Photo: Orexo / PR

Swedish biotech firm Orexo is ready to enter the clinical stage with a nasal candidate, OX640, for the emergency treatment of allergic reactions, which includes anaphylaxis, a company press release has announced.

Today’s first-line treatment response consists mostly of intramuscular adrenaline injections, which means the Swedish firm’s nasal candidate could be a potential challenger on the established allergy market. One firm operating there is Danish firm ALK with its rescue pen, Jext.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs